Business Context and Reporting Period
Company: Biomerica, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Nine and three months ended February 28, 2011
Business Overview: Biomerica develops, manufactures, and markets medical diagnostic products for the early detection of chronic diseases. Products are sold to clinical laboratories and point-of-care markets (physicians' offices and drugstores) globally. The company operates manufacturing facilities in Irvine, California, and Mexicali, Mexico.
Key Financial Metrics
| Metric | Nine Months Ended Feb 28, 2011 | Nine Months Ended Feb 28, 2010 | Three Months Ended Feb 28, 2011 | Three Months Ended Feb 28, 2010 |
|---|---|---|---|---|
| Net Sales | $3,684,454 | $3,678,076 | $1,345,900 | $1,429,675 |
| Gross Profit | $1,188,804 | $1,107,680 | $499,479 | $514,726 |
| Gross Margin | 32.3% | 30.1% | 37.1% | 36.0% |
| Operating Income (Loss) | $(116,830) | $(187,305) | $73,015 | $114,175 |
| Net Income (Loss) | $61,354 | $(164,147) | $73,403 | $133,625 |
| Cash and Equivalents (End of Period) | $904,062 | $1,055,206 | N/A | |
| Working Capital | $3,212,894 | $3,241,717 | N/A | |
| Total Debt (Current + Long Term) | $46,949 | $80,499 | N/A |
Material Changes vs. Prior Period
- Revenue: Nine-month net sales remained flat (up 0.2% to $3.68M), while the most recent quarter saw a 5.9% decline to $1.35M, attributed to lower domestic sales for colorectal screening programs.
- Profitability: The company returned to profitability for the nine-month period ($61k net income) compared to a loss of $164k in the prior year. This turnaround was significantly driven by a non-recurring research grant.
- Cost of Sales: Improved from 69.9% of sales in the prior year to 67.7% for the nine months ended Feb 2011. Prior year costs were negatively impacted by facility moves and scrap; current year costs include provisions for free kits earned by a distributor.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased 3.3% year-over-year for the nine-month period. Research and development (R&D) expenses increased 16.3% due to costs associated with newly licensed products.
- Cash Flow: Operating cash flow turned positive at $65,888 for the nine months, compared to a usage of $232,872 in the prior year. This improvement was due to the collection of receivables and utilization of prepaid assets, offset by payments to reduce accounts payable and accrued compensation.
Guidance, Outlook, and Risks
- Unusual Items: Net income for the nine months ended Feb 28, 2011, includes approximately $173,648 in "Other Income" derived from a Qualifying Therapeutic Discovery Project grant (Section 48D of the Internal Revenue Code). The company anticipates receiving the remaining approved funds of approximately $140,000 shortly after the fiscal year-end.
- Capital Resources: A $400,000 line of credit expired on February 13, 2011. The company is negotiating a renewal or alternative financing, but there is no assurance of success. An equipment loan of approximately $47,000 remains outstanding.
- Strategic Shift: Post-period, the company eliminated its dedicated research department to pursue a strategy of licensing technology from external institutions.
- Risks: Key risks include dependence on international distributors, potential loss of major customers (one customer represented 36.8% of gross receivables), regulatory approval delays, and the ability to secure additional financing.
Investor Verification Checklist
- Grant Sustainability: Verify the timing and certainty of the remaining $140,000 government grant, as current profitability is heavily influenced by this non-operating income.
- Financing Status: Confirm the status of the expired $400,000 line of credit and the company's ability to secure replacement liquidity.
- Customer Concentration: Assess the risk associated with the top customer holding 36.8% of gross receivables and the impact of their payment terms.
- Revenue Quality: Review the impact of the "free kits" agreement with a distributor on future cost of sales and gross margins.
- Strategic Execution: Monitor the transition from internal R&D to a licensing model and its effect on future product pipelines and expense structures.